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1 The potential for the N-hydroxyguanidine compound PR5 (N-(3,4-dimethoxy-2-chlorobenzyli-
deneamino)-N'-hydroxyguanidine) as a cardioprotective agent in heart ischaemia and reperfusion
injury was investigated using rat models.
2 Administration of 1 ± 10 mg kg71 of PR5 5 min before 10 min of left coronary artery occlusion,
followed by 20 min reperfusion, strongly inhibited reperfusion burst of arrhythmias and markedly
improved the survival of the animals (e.g. ventricular ®brillation incidence 93 vs 43% (P50.05);
mortality 47 vs 0% (P50.05), for controls and for 3 mg kg71 of PR5, respectively).
3 Administration of 3 mg kg71 of PR5 1 min before reperfusion to rats subjected to 10 min
occlusion, 20 min reperfusion was most eective in reducing arrhythmias and decreasing mortality
(43 vs 0%, P50.05), but eects were also seen when PR5 was administered 0, 1 and 5 min after
start of reperfusion.
4 Coronary occlusion/reperfusion (10 ± 20 min) increased malondialdehyde (MDA) of rat hearts
(0.88+0.13 for sham vs 1.45+0.12 nmol mg71 protein for ischaemic; P50.05). In rats where
3 mg kg71 PR5 were administered 1 min before reperfusion the increase was attenuated (MDA
being 1.04+0.12; P50.05 vs ischaemic).
5 PR5 caused a substantial reduction of the infarction size in rats subjected to 180 min left
coronary artery occlusion, followed by 120 min of reperfusion; the necrotic zone being 326+32 mg
for controls vs 137+21 mg for animals treated with 363 mg kg71 of PR5 (P50.01).
6 PR5 reduced the elevation of the ST-segment of the ECGs, as well as caused pronounced
attenuation of the rapid blood pressure drop seen at the start of reperfusion following coronary
artery occlusion.
7 We conclude that the N-hydroxyguanidine PR5 provides remarkable protection against
ischaemia and reperfusion induced myocardial necrosis and life-threatening arrhythmias. These
eects of PR5 are discussed in relation to a recently discovered ability of N-hydroxyguanidines to
function as electron acceptors at the xanthine oxidase enzyme.
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Abbreviations: ECG, electrocardiogram; MDA, malondialdehyde; PR5, N-(3,4-Dimethoxy-2-chlorobenzylideneamino)-N'-
hydroxyguanidine; VT, ventricular tachycardia; VF, ventricular ®brillation
Introduction
Ischaemia followed by reoxygenation is associated with oxygen
free radical generation, which is one of the major factors in the
induction of arrhythmias and myocardial damage in the
ischaemia and reperfusion syndrome. Several mechanisms are
involved in the generation of oxygen free radicals (Ar'Rajab et
al., 1996). Among others, the reduction of molecular oxygen
by the xanthine oxidase enzyme (EC 1.1.3.22) during oxidation
of hypoxanthine and xanthine is of crucial importance
(McCord, 1985; Reilly et al., 1991). It is proposed that the
free radical generation is dependent on the ischaemia-induced
conversion of xanthine dehydrogenase to xanthine oxidase by
partial proteolytic cleavage and sulphydryl oxidation (Amaya
et al., 1990; Poss et al., 1996). As a result, the enzyme is unable
to reduce its natural electron accepting substrate NAD+ and
instead prefers molecular oxygen, which leads to the
generation of oxygen centred radicals (Nishino et al., 1994;
Saugstad, 1996).
Various methods have been tried to prevent the
formation of oxygen reactive species during reperfusion.
Thus, according to the xanthine oxidase hypothesis
inhibitors of the enzyme, such as allopurinol and oxypur-
inol, were reported to decrease radical generation and heart
injury (Castelli et al., 1995; Thompson-Gorman & Zweier,
1990). Also an inhibitor of adenosine deaminase was shown
to reduce the formation of oxygen radicals and to improve
the contractile performance of hearts in vitro, an eect
presumed to be due to the inhibition of the formation of the
reducing substrates for xanthine oxidase (Xia et al., 1996).
Still another approach is to use radical scavenging
compounds (Opie, 1989; Flaherty & Weisfeldt, 1988). Lipid
peroxidation inhibitory aminosteroids (lazaroids) have been
shown to protect eectively against heart injury in infarction
models in vivo (Campo et al., 1996; 1997). Earlier much
attention was paid to superoxide dismutase for quenching
superoxide, but its use as a protector against ischaemia and
reperfusion injuries has generally led to disappointment
(Vanhaecke et al., 1991; Watanabe et al., 1993). Recently,
however, it was found that overexpression of superoxide
dismutase in transgenic mice led to reduction of superoxide,
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improvement of heart contractility and reduction of
infarction size in reperfused hearts after ischaemia (Wang
et al., 1998).
In the present study we have evaluated a new possibility
to protect the heart in ischaemia and reperfusion. The
approach originates from our recent ®nding that an N-
hydroxyguanidine, guanoxabenz (1-(2,6-dichlorobenzylide-
neamino)-3-hydroxyguanidine), an a2-adrenoceptor active
antihypertensive drug (Ledoux et al., 1981), could also act
as an alternative electron acceptor in xanthine oxidase
catalyzed oxidation of xanthine (Dambrova et al., 1998). In
the continuation of these studies we synthesized a novel
series of N-hydroxyguanidines and evaluated their capacity
to function as electron acceptors in bovine milk xanthine
oxidase catalyzed oxidation of xanthine. We then found N-
(3,4-dimethoxy-2-chlorobenzylideneamino)-N'-hydroxyguani-
dine (PR5), which shows higher activity than guanoxabenz
on the xanthine oxidase and seems to be essentially devoid




Male Wistar rats (Latvian State Pharmaceutical Company
`Grindex', Latvia) weighing 330 ± 420 g were housed under
standard conditions (21 ± 238C, 12 h light-dark cycle) with
unlimited access to food and water. All experimental
procedures were performed in accordance with the regulations
of the Animal Ethical Committee of BaltLASA.
Ischaemia and reperfusion induced heart failure
The experimental procedure was a modi®cation of the
method by Kane et al. (1984). Rats were anaesthetized with
sodium pentobarbital (60 mg kg71 i.p.). The femoral vein
was cannulated to allow administration of drugs. Systemic
blood pressure was registered from the left carotid artery by
a pressure transducer P23 DB (Gould Statham, U.S.A.) and
ECG from a II standard lead on a physiograph DMP-4B
(Narco Bio-Systems, U.S.A.). Rats were intubated through a
tracheotomy and ventilated with room air by a V5kG
respirator (Narco Bio-Systems, U.S.A.) at a pressure of
15 cm H2O and a rate of 55 strokes min
71. The chest was
opened and a sling (6/0 silk Ethicon) was placed around the
left coronary artery. After 10 min the coronary artery was
occluded by applying tension to the plastic tube-silk string
arrangement. The successful occlusion was con®rmed by a
decrease in arterial pressure and ischaemia-induced altera-
tions in the ECG. Reperfusion was initiated by removing the
clamp.
Experimental protocols
Three protocols with separate control groups were carried out
as follows:
I Dose eect evaluation of PR5 on rats subjected to 10 min
ischaemia and 20 min reperfusion The rats were randomly
divided into four groups: (1) (n=15) received saline vehicle
(2 ml kg71); (2) (n=14), (3) (n=14) and (4) (n=14) received 1,
3 and 10 mg kg71 PR5, respectively. Saline and PR5 were
administered by a single intravenous injection (i.v.) 5 min prior
to the ischaemia.
II Evaluation of the importance of the dosing schedule for the
eects of PR5 on rats subjected to 10 min ischaemia and 20 min
reperfusion The rats were randomly divided into ®ve groups:
(1) (n=14) received saline (2 ml kg71 i.v.) at the ninth min of
the occlusion; (2) (n=14) 3 mg kg71 i.v. of PR5 at the ninth
min of occlusion; (3) (n=12) 3 mg kg71 i.v. of PR5 at the
onset of reperfusion; (4) (n=10) 3 mg kg71 i.v. of PR5 at the
®rst min of reperfusion and (5) (n=10) 3 mg kg71 i.v. of PR5
at the ®fth min of reperfusion.
III The in¯uence of PR5 on functional status and morphology of
the heart in rats subjected to 180 min ischaemia and 120 min
reperfusion The rats were randomly divided into ®ve groups:
(1) (n=15) received saline (2 ml kg71 i.v.) 5 min prior to
occlusion; (2) (n=12) 3 mg kg71 i.v. of PR5 5 min prior to
occlusion; (3) (n=13) rats 3 mg kg71 i.v. of PR5 170 min after
occlusion; (4) (n=14) 3 mg kg71 i.v. of PR5 at the ®fth min of
reperfusion and (5) (n=13) 3 mg kg71 i.v. of PR5 at three
times; namely: 5 min prior to occlusion, 170 min after
occlusion and at the ®fth min of reperfusion.
Exclusion criteria
Experiments were terminated and data were excluded from the
®nal analysis if arrhythmias occurred prior to the coronary
artery occlusion; if the mean arterial pressure was less than
60 mmHg prior to occlusion (drug or saline administration),
or if severe arrhythmias or atrioventricular block occurred
during the ®rst 5 min of ischaemia.
De®nition of arrhythmias
De®nition of arrhythmias were based on criteria described in
the Lambeth Conventions (Walker et al., 1988). Ectopic
activity was categorized as a single ventricular premature beat
(VPB), ventricular tachycardia (VT) or as ventricular
®brillation (VF). In all experiments the incidence of VT, VF
and mortality (due to terminal ventricular ®brillation sustained
for at least 3 min) was noted.
Quanti®cation of myocardial morphological parameters
At the end of reperfusion of the animals subjected to
experimental protocol III the ligature was re-tied around the
coronary artery and Evans blue (5 mg ml71) was quickly
infused into the left atrium. The heart was then isolated,
weighed and the left ventricle was dissected free from other
structures and weighed. The non-stained myocardium was
isolated, weighed and cut into 1 mm sections. The sections
were incubated in a 0.5% solution of triphenyltetrazolium
chloride (10 min at 378C). After that the necrotic tissues were
isolated and weighed.
Determination of malondialdehyde (MDA)
The rats were randomly divided into three groups: One
ischaemia and reperfusion control group (i.e. group (1) in
experimental protocol II, n=9); one PR5-treated group
(i.e. group (2) in experimental protocol II, n=9) and one
sham operated group (n=8), subjected to the same
surgical procedures as experimental protocol II, except
that the suture passed around the left coronary artery was
not tied. The rats were then subjected to 10 min occlusion/
20 min reperfusion, whereafter the chests were reopened,
the hearts excised and the ventricles immediately frozen
using previously cooled clamps. The MDA levels were
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determined according to the method of Ohkawa et al.
(1979).
Statistics
The results are presented as the mean+s.e.mean. Statistical
analysis was performed using ANOVA followed by
Dunnett's t-test; the number of incidence of arrhythmia
and mortality were analysed using Chi-square tests. Results
were considered as signi®cant when P50.05. The number
of incidences of arrhythmia and lethality were calculated
in all animals, whereas only the data obtained for the
surviving animals were used in the evaluation of the blood
pressure, heart rate, duration of arrhythmia and morpho-
logical data.
Results
The dose eect relations of PR5 on rats subjected to
10 min ischaemia and 20 min reperfusion
The experimental protocol I procedures caused disturbances of
the heart rhythm in all control rats, with seven out of 15 rats
dying due to irreversible ventricular ®brillation (Figure 1). As
can be seen from Figure 1, PR5 in a dose dependent fashion
reduced the incidence of VT, VF and mortality, the eect being
signi®cant at 3 and 10 mg kg71 for mortality and ®brillation,
and at 10 mg kg71 for tachycardia.
Figure 2A shows the eect on the blood pressure. In
controls the coronary artery occlusion caused an initial drop
in the blood pressure of 20 ± 25 mmHg, with the blood
pressure thereafter slightly recovering. In the saline treated
group the start of reperfusion caused a drastic decrease in
the blood pressure of 45 ± 50 mmHg during the ®rst minutes
of reperfusion, which was then rapidly followed by a
rebound increase in the pressure (Figure 2A). The
administration of 1, 3 and 10 mg kg71 of PR5 caused a
dose dependent and signi®cant inhibition in reperfusion
induced drop in blood pressure, as well as inhibition of the
rebound increase in pressure. As seen from the Figure 2A,
PR5 did not aect the initial ischaemia-induced blood
pressure drop.
Figure 2B shows the eect of PR5 on heart rate. The two
higher doses of PR5 appeared to cause some drop in heart rate,
which then returned to essentially normal during the course of
the experiment.
Figure 2C shows the eects of PR5 on the ST-segment
elevation. As expected, the ischaemia caused a progressive
increase in the ST-segment, which then almost normalized
during reperfusion. The PR5 caused a dose-dependent
inhibition in the ST-segment elevation during the ischaemia
and improved the normalization of ST-segment during
reperfusion; the eects being signi®cant at 3 and 10 mg kg71
of PR5.
The dosing schedule for the eect of PR5 on arrhythmia
and mortality in rats subjected to 10 min ischaemia and
20 min reperfusion
The next set of experiments was designed to evaluate the
importance for the time point of administration of PR5. Based
on the studies above, we selected a PR5 dose of 3 mg kg71 i.v.
The same ischaemia and reperfusion protocol as above was
used, but PR5 was administered at dierent times (protocol
II).
Also in these tests reperfusion induced VT and VF, as well
as death of many of the control animals. Thus, tachycardia
was observed in all animals, ®brillation in 100% (14/14), and
almost half (6/14) of the animals died (Figure 3). However,
PR5 had a marked eect on these parameters (Figure 3), the
largest eect being seen when PR5 was administered 1 min
prior to reperfusion (Group 2); the incidence of tachycardia
and ®brillation being reduced to 43% (6/14) and 21% (3/14),
respectively, and all (0/14) of the animals surviving (P50.05).
Similar bene®cial eect was seen when PR5 was administered
simultaneously with the start of reperfusion (Group 3).
Figure 4 further ampli®es the time course in individual
animals for the occurrence of arrhythmias. Figure 4A shows
data for the controls where VT and VF increased markedly at
the start of reperfusion, and then gradually declined. For the
animals receiving PR5 1 min prior to reperfusion (Figure 4B)
life threatening arrhythmias became markedly decreased
during the ®rst minutes, and only few occasions of arrhythmias
were registered thereafter.
Eect of PR5 on MDA
Figure 5 shows MDA levels in hearts excised after 10 min
ischaemia and 20 min reperfusion. In the coronary occlusion/
Figure 1 Eects of PR5 on the incidence of ventricular tachycardia (VT) and ®brillation (VF) during a 20 min reperfusion period
following a 10 min left coronary occlusion in rats. PR5 (1, 3 or 10 mg kg71) or saline control injections were given i.v. 5 min prior
to the coronary occlusion. (*Indicates P50.05).
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reperfusion group MDA was signi®cantly elevated compared
to sham-operated animals. For the animals treated with
3 mg kg71 of PR5 1 min prior to reperfusion there was a
statistically signi®cant inhibition of the MDA formation
compared to the non-treated ischaemia and reperfusion
animals (P50.05).
In¯uence of PR5 on functional status and morphology of
rat hearts during 180 min ischaemia and 120 min
reperfusion
In these tests the rats were treated according to the
experimental protocol III. Results are presented in Table 1
Figure 2 Eect of PR5 on blood pressure (A), heart rate (B) and ST-segment (C) in rats subjected to 10 min left coronary artery
occlusion followed by 20 min reperfusion. PR5 (1, 3 or 10 mg kg71) or saline control injections were given i.v. 5 min prior to the
coronary occlusion. (*Indicates P50.05; **Indicates P50.01).
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and Figure 6. ANOVA showed that body weights, heart and
left ventricle weights were essentially the same for all the ®ve
dierent groups (Table 1), indicating that the groups were well
matched. Also the weight of the ischaemic zones caused by the
coronary artery occlusion were of almost the same size (Table
1). However, the weight of the necrotic tissue was markedly
reduced by the treatment with PR5; the eect being highly
signi®cant (P50.01) for the Group 2, as well as Groups 3 and
4. Figure 6 shows the data normalized against ventricle and
ischaemic zone weights. The largest reduction of infarction size
is seen for Group 2, followed by Groups 3 and 4.
Figure 7 shows the time course for the deviation of the ST-
segment from the baseline throughout the ischaemia and
reperfusion periods. The ischaemia caused an increase in the
ST-segment, from about 0.1 mV to about 0.5 mV, as expected.
During reperfusion the ST-segment normalized slightly, but it
never returned to the baseline. Administration of PR5 gave a
highly signi®cant attenuation in the increase of the ST-segment
during almost the whole ischaemic period, that extended also
into reperfusion period (Groups 3 and 4). When PR5 was given
363 mg kg71 (Group 2) the normalizing eect on the ST-
segment increase was pronounced and highly signi®cant
throughout the whole ischaemia and reperfusion periods
(P50.0001) (Figure 7).
Discussion
We have here shown that the hydroxyguanidine compound
PR5 possesses a remarkable ability to protect the rat heart
during reperfusion. Thus, PR5 strongly inhibited the burst of
arrhythmias associated with reperfusion of ischaemic hearts,
and it markedly improved the survival of the animals. Most
notably, PR5 caused a substantial reduction (i.e. more than 2
fold at the best dosing schedule) of the infarction size, after
180 min of ischaemia followed by 120 min of reperfusion.
These eects were associated with a reduction of the ischaemia
induced elevation of the ST-segment of the ECGs, as well as a
pronounced attenuation of the rapid blood pressure drop seen
at the start of reperfusion, results which further indicate a
strong protective eect by PR5 on the hearts haemodynamic
function and/or its antiarrhythmic eect.
In a previous study we showed that the hydroxyguanidine
guanoxabenz was capable of supporting the oxidation of
xanthine to uric acid both during anaerobic and aerobic
conditions (Dambrova et al., 1998). In subsequent studies we
synthesized a novel series of hydroxyguanidines and found that
PR5 showed a higher capacity than guanoxabenz to support
the anaerobic oxidation of xanthine by xanthine oxidase
(Dambrova et al. manuscript in preparation). From these
results we hypothesized that PR5 could be useful in protecting
the heart during ischaemia and reperfusion. It is well known
that the ischaemia induces a rapid accumulation of hypox-
anthine and xanthine due to the breakdown of the cellular
ATP-pools due to insucient oxidative phosphorylation (Xia
et al., 1996; Saugstad, 1996). At the same time the release of
intracellular proteolytic enzymes may cause a conversion of
the xanthine dehydrogenase enzyme to its oxidase form. Upon
the eventual reoxygenation of the tissue a rapid oxidation of
hypoxanthine and xanthine will proceed, followed by the
concomitant massive formation of toxic superoxide radicals
(McCord, 1985). The thus formed free radicals may be
responsible for the various injuries, which include life-
threatening arrhythmias and cell death (Flaherty & Weisfeldt,
1988). However, additional mechanisms may also prevail that
contribute to the damage (Bolli, 1988; Piper et al., 1998).
Thus, if PR5 is administered prior to deprivation of the
blood supply to an organ it might be capable of supporting the
oxidation of the hypoxanthine and xanthine during the
ischaemia. Upon a subsequent reoxygenation there would
then be present less oxidizable substrate (e.g. xanthine and
hypoxanthine) for the xanthine oxidase, which accordingly
would prevent formation of oxyradicals. It is also possible that
in the presence of oxygen the hydroxyguanidine could accept
the electrons generated during the hypoxanthine/xanthine
oxidation, thus preventing the formation of oxyradicals.
Although at present the above described mechanism of
action for PR5 is only hypothetical, the data of the present
study support the hypothesis. In the present paper we have
observed that the antiarrhythmic eect of PR5 is observed only
during reperfusion, whereas no signi®cant eect is seen during
coronary artery occlusion. It is well accepted that the
arrhythmias seen at the onset of reperfusion are caused by
the massive formation of oxyradicals (Opie, 1989), thus
Figure 3 Eect of 3 mg kg71 of PR5 injected at dierent time points during 10 min left coronary artery occlusion followed by
20 min reperfusion on the incidence of ventricular tachycardia (VT), ®brillation (VF) and mortality during reperfusion. Shown are
saline injected animals (1 Control), animals injected with PR5 on the ninth min of occlusion (2 occlusion 9 min), animals injected
with PR5 at the onset of reperfusion (3 reperfusion 0 min), animals injected with PR5 1 min after start of reperfusion (3 reperfusion
1 min), and animals injected with PR5 5 min after the start of reperfusion (5 reperfusion 5 min). (*Indicates P50.05).
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indicating that the PR5 eect is linked to the radicals. It is
interesting to note that PR5 has eect on the ST-segment also
during the occlusion period (Figure 2C and 7). It is possible
that this eect is due to the anaerobic oxidation of the xanthine
oxidase substrates. Moreover, the results for MDA support an
anti-oxidant mechanism for PR5. Still, of course, further
studies will be necessary to prove the hypothesis for the mode
of action of PR5.
Previous attempts to prevent toxic eects due to oxygen
radical formation associated with ischaemia and reperfusion
have been mainly focused on removing the superoxide or
hydroxyradicals after their production. Thus, for example,
compounds like lazaroids and a vitamin E analogue
(raxofelast) are shown to prevent lipid peroxidation, possess
antioxidant properties and have bene®cial eects in models of
myocardial damage (Campo et al., 1997; 1998). Another
direction was to use xanthine oxidase inhibitors to prevent the
oxidation of hypoxanthine/xanthine and oxyradical genera-
tion. Thus, allopurinol was reported to improve cardiac
function in coronary artery bypass surgery (Castelli et al.,
Figure 4 Occurrence of arrhythmia and death (exitus letalis) in individual animals during the course of 10 min ischaemia followed
by 20 min reperfusion. Shown are data for control animals (A) and data for animals treated with 3 mg kg71 of PR5 at the ninth
min of occlusion (B).
Figure 5 Eect of PR5 on malondialdehyde (MDA) in rat hearts
subjected to ischaemia reperfusion. Sham=sham operated, IR=
ischaemia reperfusion control, IR+PR5=PR5 treated (3 mg kg71)
ischaemia reperfusion animals. For further details see text. (*In-
dicates P50.05 vs IR; #Indicates P50.05 vs sham).
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Figure 6 Eects of PR5 on ischaemic zone/left ventricular size index, necrotic zone/left ventricular size index and necrotic zone/
ischaemic zone size index in rats subjected to 180 min left coronary artery occlusion followed by 120 min reperfusion. Shown are
data for control animals (1), animals receiving 363 mg kg71 of PR5, respectively 5 min before occlusion, 170 min after occlusion
and 5 min after start of reperfusion (2), animals receiving 3 mg kg71 of PR5 5 min before occlusion (3), animals receiving
3 mg kg71 of PR5 170 min after occlusion (4), and animals receiving 3 mg kg71 of PR5 5 min after start of reperfusion (5)
ANOVA showed signi®cant eects for necrotic zone/left ventricle F(1,49)=2.18; P50.01 and necrotic zone/ischaemic zone
F(1,49)=6.03; P50.0001. (*Indicates P50.05; **P50.01).
Figure 7 Eects of PR5 on ST-segment in rats during 180 min left coronary artery occlusion followed by 120 min reperfusion.
Shown are data for control rats as well as data for animals receiving 363 mg kg71 of PR5, respectively 5 min before occlusion,
170 min after occlusion and 5 min after start of reperfusion (2), animals receiving 3 mg kg71 of PR5 5 min before occlusion (3),
animals receiving 3 mg kg71 of PR5 170 min after occlusion (4), and animals receiving 3 mg kg71 of PR5 5 min after start of
reperfusion (5). (*Indicates P50.05, **P50.01 vs the control).
Table 1 Body weight and weight of hearts, left ventricle, ischaemic zone and necrotic zone in rats subjected to 180 min left coronary
artery occlusion followed by 120 min reperfusion
Body weight Heart weight Left ventricle Ischaemic zone Necrotic zone




































Shown are data for control rats as well as data for animals receiving 363 mg kg71 of PR5, respectively 5 min before occlusion,
170 min after occlusion and 5 min after start of reperfusion (2), animals receiving 3 mg kg71 of PR5 5 min before occlusion (3),
animals receiving 3 mg kg71 of PR5 170 min after occlusion (4), and animals receiving 3 mg kg71 of PR5 5 min after start of
reperfusion (5). **Indicates P50.01.
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1995). Also an inhibitor of adenosine deaminase was shown to
reduce the formation of oxygen radicals, an eect assumed to
be due to the inhibition of the accumulation of the oxidizing
substrates for xanthine oxidase (Xia et al., 1996). It should be
also mentioned, that methylene blue, which is known to inhibit
the generation of oxygen radicals by competing with molecular
oxygen for the reduction of the latter by xanthine oxidase
(Salaris et al., 1991), was recently found to prevent pulmonary
injury after intestinal ischaemia and reperfusion (Galili et al.,
1998), but its eventual eect in the heart has not yet been
evaluated. Moreover, the mechanism of action of methylene
blue is quite uncertain. The compound is also a soluble
guanylate cyclase inhibitor, and it has been found to increase
the incidence of reperfusion-induced ventricular ®brillation
(Pabla et al., 1995).
The N-hydroxyguanidine guanoxabenz have been used as
centrally active antihypertensive drug (Ledoux et al., 1981),
but any possible antiischaemic eect of the guanoxabenz has
not been reported. In the present study we have shown that the
N-hydroxyguanidine PR5 provides remarkable protection
against ischaemia and reperfusion induced myocardial necrosis
and life-threatening arrhythmias. Since PR5 can act as an
alternative electron acceptor for xanthine oxidase enzyme in
vitro, we have hypothesized that xanthine oxidase-related
mechanism of action may be a reason for its cardioprotective
action.
In conclusion, we have shown that the N-hydroxyguanidine
PR5 provides marked protection against ischaemia and
reperfusion induced myocardial necrosis and life-threatening
arrhythmias. Moreover, we have provided evidence that the rat
heart lipid peroxidation damage (estimated as MDA forma-
tion) is inhibited by PR5. These eects of PR5 might be related
to the recently discovered ability of N-hydroxyguanidines to
function as electron acceptors at the xanthine oxidase enzyme.
We are grateful for technical assistance by Romans Sjomins,
Latvian Institute of Organic Synthesis, Riga, Latvia. PR5 was
synthesized by Dr Viktors Andrianovs at the Department of
Medicinal Chemistry, Latvian Institute of Organic Synthesis, Riga,
Latvia. This study was supported by the Swedish MRC (04X-05957)
and the AÊ ke Wiberg foundation. Dr Maris Veveris was supported by
a stipend from the Swedish Institute.
References
AMAYA, Y., YAMAZAKI, K., SATO, M., NODA, K., NISHINO, T. &
NISHINO, T. (1990). Proteolytic conversion of xanthine dehy-
drogenase from the NAD-dependent type to the O2-dependent
type. J. Biol. Chem., 265, 14170 ± 14175.
AR'RAJAB, A., DAWIDSON, I. & FABIA, R. (1996). Reperfusion
injury. New Horizons, 4, 224 ± 234.
BOLLI, R. (1998). Basic and clinical aspects of myocardial stunning.
Progr. Cardiovasc. Dis., 40, 477 ± 516.
CAMPO, G.M., SQUADRITO, F., ALTAVILLA, D., SQUADRITO, G.,
AVENOSO, A., CANALE, P., LOCULANO, M., SPERANDEO, A. &
CAPUTI, A.P. (1996). Protection of ischemic and reperfused rat
myocardium by the nonglucocorticoid 21-aminosteroid U-
74389G, a new inhibitor of lipid peroxidation. J. Pharmacol.
Exp. Ther., 277, 333 ± 340.
CAMPO, G.M., SQUADRITO, F., CAMPO, S., ALTAVILLA, D.,
AVENOSO, A., FERLITO, M., SQUADRITO, G. & CAPUTI, A.P.
(1997). Antioxidant activity of U-83836E, a second generation
lazaroid, during myocardial ischaemia/reperfusion injury. Free
Radic. Res., 27, 577 ± 590.
CAMPO, G.M., SQUADRITO, F., CAMPO, S., ALTAVILLA, D.,
QUARTARONE, C., CECCARELLI, S., FERLITO, M., AVENOSO,
A., SQUADRITO, G., SAITTA, A. & CAPUTI, A.P. (1998). Bene®cial
eect of raxofelast, an hydrophilic vitamin E analogue, in the rat
heart after ischaemia and reperfusion injury. J. Mol. Cell
Cardiol., 30, 1493 ± 1503.
CASTELLI, P., CONDEMI, A.M., BRAMBILLASCA, C., FUNDARO, P.,
BOTTA, M., LEMMA, M., VANELLI, P., SANTOLI, C., GATTI, S. &
RIVA, E. (1995). Improvement of cardiac function by allopurinol
in patients undergoing cardiac surgery. J. Cardiovasc. Pharma-
col., 25, 119 ± 125.
DAMBROVA, M., UHLEÂ N, S., WELCH, C.J. & WIKBERG, J.E.S. (1998).
Identi®cation of an N-hydroxyguanidine reducing activity of
xanthine oxidase. Eur. J. Biochem., 257, 178 ± 184.
FLAHERTY, J.T. & WEISFELDT, M.L. (1988). Reperfusion injury.
Free Radic. Biol. Med., 5, 409 ± 419.
GALILI, Y., BEN-ABRAHAM, R., WEINBROUM, A., MARMUR, S.,
IAINA, A., VOLMAN, Y., PEER, G., SZOLD, O., SOFFER, D.,
KLAUSNER, J., RABAU, M. & KLUGER, Y. (1998). Methylene
blue prevents pulmonary injury after intestinal ischaemia-
reperfusion. J. Trauma, 45, 222 ± 226.
KANE, K.A., PARRATT, J.R. & WILLIAMS, F.M. (1984). An
investigation into the characteristics of reperfusion-induced
arrhythmias in the anaesthetised rat and their susceptibility to
antiarrhythmic agents. Br. J. Pharmacol., 82, 349 ± 357.
LEDOUX, F., WELSC, M., STEIMER, C. & SCHWARTZ, J. (1981). A
clinical trial of guanoxabenz: a hypotensive agent with central
and hypertensive action. Therapie, 36, 187 ± 191.
MCCORD, J.M. (1985). Oxygen-derived free radicals in postischemic
tissue injury. N. Eng. J. Med., 312, 159 ± 163.
NISHINO, T. (1994). The conversion of xanthine dehydrogenase to
xanthine oxidase and the role of the enzyme in reperfusion injury.
J. Biochem., 116, 1 ± 6.
OHKAWA, O., OHISHI, N. & YAGI, K. (1979). Assay for peroxides in
animal tissues by thiobarbituric acid reaction. Anal. Biochem.,
95, 351 ± 358.
OPIE, L.H. (1989). Reperfusion injury and its pharmacologic
modi®cation. Circulation, 80, 1049 ± 1062.
PABLA, R., BLAND-WARD, P., MOORE, P.K. & CURTIS, M.J. (1995).
An endogenous protectant eect of cardiac cyclic GMP against
reperfusion-induced ventricular ®brillation in the rat heart. Br. J.
Pharmacol., 116, 2923 ± 2930.
PIPER, H.M., GARCIA-DORADO, D. & OVIZE, M. (1998). A fresh look
at reperfusion injury. Cardiovasc. Res., 38, 291 ± 300.
POSS, W.B., HUECKSTEADT, T.P., PANUS, P.C., FREEMAN, B.A. &
HOIDAL, F.J. (1996). Regulation of xanthine dehydrogenase and
xanthine oxidase activity by hypoxia. Am. J. Physiol., 270,
L941 ± L946.
REILLY, P.M., SCHILLER, H.J. & BULKLEY, G.B. (1991). Pharmaco-
logical approach to tissue injury mediated by free radicals and
other reactive oxygen metabolites. Am. J. Surg., 161, 488 ± 503.
SALARIS, S.C., BABBS, C.F. & VOORHEES III W.D. (1991). Methylene
blue as an inhibitor of superoxide generation by xanthine
oxidase. Biochem. Pharmacol., 42, 499.
SAUGSTAD, O.D. (1996). Role of xanthine oxidase and its inhibitor
in hypoxia: reoxygenation injury. Pediatrics, 98, 103 ± 107.
THOMPSON-GORMAN, S.L. & ZWEIER, J.L. (1990). Evaluation of the
role of xanthine oxidase in myocardial reperfusion injury. J. Biol.
Chem., 265, 6656 ± 6663.
VANHAECKE, J., VANDEWERF, F., RONASZEKI, A., FLAMENG,W.,
LESAFFRE, E. & DE GEEST, H. (1991). Eect of superoxide
dismutase on infarct size and postischemic recovery of myocar-
dial contractility and metabolism in dogs. J. Am. Coll. Cardiol.,
18, 224 ± 230.
WALKER, M.J.A., CURTIS, M.J., HEARSE, D.J., CAMPBELL, R.W.F.,
JANSE, M.J., YELLON, D.M., COBBE, S.M., COKER, S.J., HAR-
NESS, J.B., HARRON, D.W.G., HIGGINS, A.J., JULIAN, D.G., LAB,
M.J., MANNING, A.S., NORTHOVER, B.J., PARRATT, J.R.,
RIEMERSMA, R.A., RIVA, E., RUSSELL, D.C., SHERIDAN, D.J.,
WINSLOW, E. & WOODWARD, B. (1988). The Lambeth Conven-
tions: guidelines for the study of arrhythmias in ischaemia,
infarction and reperfusion. Cardiovasc. Res., 22, 447 ± 455.
Cardioprotective effects of N-hydroxyguanidine1096 M. Veveris et al
WANG, P., CHEN, H., QIN, H., SANKARAPANDI, S., BECHER, M.W.,
WONG, P.C. & ZWEIER, J.L. (1998). Overexpression of human
copper, zinc-superoxide dismutase (SOD1) prevents postischemic
injury. Proc. Natl. Acad. Sci. U.S.A., 95, 4556 ± 4560.
WATANABE, B.I., PREMARATNE, S., LIMM, W., MUGIISHI, M.M. &
MCNAMARA, J.J. (1993). High- and low-dose superoxide
dismutase plus catalase does not reduce myocardial infarct size
in a subhuman primate model. Am. Heart J., 126, 840 ± 846.
XIA, Y., KHATCHIKIAN, G. & ZWEIER, J.L. (1996). Adenosine
deaminase inhibition prevents free radical-mediated injury in the
postsichemic heart. J. Biol. Chem., 271, 10096 ± 10102.
(Received June 30, 1999
Revised August 5, 1999
Accepted August 8, 1999)
Cardioprotective effects of N-hydroxyguanidine 1097M. Veveris et al
